Axitinib and pazopanib, which inhibit VEGFRs, PDGFRs, FGFRs, and c-Kit, are already used clinically in renal cell carcinoma, lung cancer, and other malignancies [54–56]. Here, KIT is linked to renal cell carcinoma.